Corona Remedies makes strong market entry with impressive listing
IPO Investors Reap Solid Returns as Stock Opens Nearly 38% Higher
Strong Subscription Drives Confident Stock Market Debut
Shares of pharmaceutical firm Corona Remedies made a strong debut in both the stock exchanges on December 15, 2025, with handsome gains to the investors of IPO. The stock opened on the National Stock Exchange at ₹ 1,470, which was over a 38% gain from its issue price of ₹ 1,062. A similar trend was seen on the BSE, where the shares opened at ₹ 1,452, translating into a premium of nearly 37%, reflecting robust investor sentiment.
The company’s IPO, purely an offer for sale, helped raise about ₹655.68 crore for its existing shareholders. Each IPO lot was of 14 shares, and investors who got allotment had listing-day gains of around ₹20,000 per lot. The stellar debut underlined the market’s strong response to the company’s business fundamentals and growth outlook.
Investor interest in the issue was exceptionally high, with the IPO being subscribed more than 137 times during the bidding period. Demand was strong across all investor categories, including qualified institutional buyers, non-institutional investors, and retail participants. The company had also mobilised nearly ₹195 crore from anchor investors ahead of the public issue, adding to the confidence surrounding the listing.
Based in Ahmedabad, Corona Remedies operates in the pharmaceutical formulations segment and has a presence across multiple therapeutic areas like women’s healthcare, cardio-diabetology, pain management, and urology. Its diversified product portfolio and established market presence seem to have clicked well with investors. Market participants will keenly observe the performance of the stock as trading continues to see whether the strong momentum at listing would sustain in the secondary market also.
